Featured
-
Pre-filled Syringes & Injectable Drug Trends
Pre-filled syringes have become a preferred format, as they make it easier to handle drugs and increase dos- ing accuracy.11.23.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
AstraZeneca’s AZD1222 Meets Primary Endpoint in COVID-19
Two different dosing regimens demonstrated efficacy with one showing vaccine efficacy of 90% with no serious safety events noted.Contract Pharma Staff 11.23.20
-
Breaking News | Drug Development | Trials & Filings
Regeneron's COVID-19 Antibody Cocktail Gets EUA
Expects to have treatment doses ready for approximately 80,000 patients by the end of November, and 200,000 by the first week of January.Contract Pharma Staff 11.23.20
-
Breaking News | Collaborations & Alliances | Drug Development
Amgen Ends Cardio Alliance with Cytokinetics
Will transition the development and commercialization rights for omecamtiv mecarbil to Cytokinetics and Servier.Contract Pharma Staff 11.23.20
-
Breaking News | cGMP Manufacture | Industry News
Catalent, Blueprint Enter GAVRETO Commercial Supply Pact
Following FDA approval and tech transfer, the Catalent team in Kansas City will support commercial supply of the non-small cell lung cancer drug.Contract Pharma Staff 11.23.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
ARCA Biopharma’s AB201 for COVID-19 Gets Fast Track
Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December with trial data anticipated 2Q21.Contract Pharma Staff 11.23.20
-
Breaking News | Industry News | Promotions & Moves
Frontida BioPharma Appoints EVP Technology
Dr. Praful Agrawala brings years of pharmaceutical product development leadership experience to the company.Contract Pharma Staff 11.20.20
-
Bio News | Breaking News | cGMP Manufacture | Facilities | Fill/Finish | Industry News
August Bioservices Expands Operations in Nashville
Plans to invest $64.7 million and create 180 jobs over the next five years.Contract Pharma Staff 11.20.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Collaborations & Alliances | Industry News
Pfizer and BioNTech to Submit EUA for COVID-19 Vaccine
Expect to produce globally up to 50 million doses in 2020, up to 1.3 billion doses by the end of 2021; ready to distribute within hours after authorization.Contract Pharma Staff 11.20.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
Samsung Biologics Partners with Eli Lilly
Accelerates the delivery of Covid-19 antibody treatments.Contract Pharma Staff 11.20.20
-
Promotions & Moves
Catalent Appoints Open Innovation, Biologics, Cell and Gene Therapy VP
Behzad Mahdavi brings more than 20 years of experience in developing and implementing growth strategies in the biopharmaceutical industries.Contract Pharma Staff 11.19.20
-
Collaborations & Alliances | Drug Development
Cue Biopharma, Merck Extend Biologics Research Alliance
To develop clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.Contract Pharma Staff 11.19.20
-
Biologics, Proteins, Vaccines | Industry News
Avantor Opens New Biorepository Facility in Europe
Supports growing demand for scientific research and clinical trial sample storage.Contract Pharma Staff 11.19.20
-
Biologics, Proteins, Vaccines | cGMP Manufacture
Delpharm to Manufacture Pfizer/BioNTech mRNA Vax in France
Will begin manufacturing BNT 162b2 in April 2021 and will produce tens of millions of doses.Contract Pharma Staff 11.19.20
-
Breaking News | CRO News | Facilities | Industry News
SGS Plans to Move Its Clinical Pharmacology Unit
Increases its capacity to conduct Human Challenge studies.Contract Pharma Staff 11.18.20
- ARCA Biopharma’s AB201 for COVID-19 Gets Fast Track
- Pfizer and BioNTech to Submit EUA for COVID-19 Vaccine
- Samsung Biologics Partners with Eli Lilly
- Delpharm to Manufacture Pfizer/BioNTech mRNA Vax in France
- Pfizer, BioNTech Conclude Phase III COVID-19 Vax Study
- Almac Gets Grant From COVID-19 Therapeutics Accelerator
- DCAT President Talks COVID-19, Drug Manufacturing and Innovation
- Inspecting the Unexpected
- CureVac to Ramp Up Mfg. of COVID-19 Vax Candidate CVnCoV
- Swissmedic Begins Rolling Review of Moderna’s mRNA COVID-19 Vax
- AstraZeneca’s AZD1222 Meets Primary Endpoint in COVID-19
- Regeneron's COVID-19 Antibody Cocktail Gets EUA
- Summit Therapeutics Appoints Chief Operating Officer
- Amgen Ends Cardio Alliance with Cytokinetics
- Catalent, Blueprint Enter GAVRETO Commercial Supply Pact
- ARCA Biopharma’s AB201 for COVID-19 Gets Fast Track
- Frontida BioPharma Appoints EVP Technology
- August Bioservices Expands Operations in Nashville
- Pfizer and BioNTech to Submit EUA for COVID-19 Vaccine
- Samsung Biologics Partners with Eli Lilly
November/December 2020
- Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
- Ensuring Quality During the Transfer and Scale Up of Rx Drugs
- Inspecting the Unexpected
- Cold Chain Trends
- Catering for the Complex
- Biopharma Contract Manufacturing: Robust Growth Ahead
- DCAT President Talks COVID-19, Drug Manufacturing and Innovation
- The Single-Use Mixing Landscape: Evaluating Your Options
- Self-Medication: Flexibility for Patients and Drug Manufacturers
- Decentralized Trials Fuel AI Revolution in Clinical Research
Contract Service Directory
Search the Directories for A Company:
